Most cited papers from Goshen Health

Goshen Health

What are the most cited papers from Goshen Health?

The most cited paper from Goshen Health is "gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma" (Douglas J. Schwartzentruber et al., 2011), with 904 citations. Next come "Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer: The Hoosier Oncology Group and U.S. Oncology" (499) and "Variation in external beam treatment plan quality: An inter-institutional study of planners and planning systems" (489).

Published TypeFieldAccessCitations

Showing 50 of 60 papers. Every paper with more than 31 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma Douglas J. Schwartzentruber et al. · New England Journal of Medicine Open access	Jun 2011	904
2	Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer: The Hoosier Oncology Group and U.S. Oncology Nasser H. Hanna, Marcus A. Neubauer, Constantin Theodore Yiannoutsos et al. · Journal of Clinical Oncology	11 Nov 2008	499
3	Variation in external beam treatment plan quality: An inter-institutional study of planners and planning systems Benjamin E. Nelms, Greg J. Robinson, Jay Markham et al. · Practical Radiation Oncology	10 Jan 2012	489
4	Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial Aditya Bardia et al. · Annals of Oncology Open access	18 Mar 2021	400
5	Compassion fatigue in nurses Elizabeth A. Yoder · Applied Nursing Research	28 Oct 2010	376
6	First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors Alexander Starodub, Allyson J. Ocean, Manish A. Shah et al. · Clinical Cancer Research Open access	5 May 2015	351
7	Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma Antoni Ribas, Donald P. Lawrence, Victoria G. Atkinson et al. · Nature Medicine Open access	Jun 2019	331
8	Variations in the Contouring of Organs at Risk: Test Case From a Patient With Oropharyngeal Cancer Benjamin E. Nelms, Wolfgang A. Tomé, Greg J. Robinson et al. · International Journal of Radiation OncologyBiologyPhysics	2 Dec 2010	245
9	Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics Allyson J. Ocean, Alexander Starodub, Aditya Bardia et al. · Cancer Open access	30 May 2017	244
10	Evaluating IMRT and VMAT dose accuracy: Practical examples of failure to detect systematic errors when applying a commonly used metric and action levels Benjamin E. Nelms, Maria F. Chan, GENEVIÈVE JARRY et al. · Medical Physics Open access	25 Oct 2013	235
11	Dosimetric techniques in 90Y-microsphere therapy of liver cancer: The MIRD equations for dose calculations. Seza A. Güleç, Geraldine Mesoloras, Michael Stabin · PubMed	Jul 2006	171
12	A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179 Greg Andrew Durm, Salma K. Jabbour, Sandra K. Althouse et al. · Cancer Open access	22 Jul 2020	169
13	Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan Jhanelle E. Gray et al. · Clinical Cancer Research Open access	5 Jul 2017	163
14	Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: The tumor selectivity of the treatment as a function of tumor to liver flow ratio Seza A. Güleç, Geraldine Mesoloras, William A. Dezarn et al. · Journal of Translational Medicine Open access	14 Mar 2007	155
15	A C-X-C Chemokine Receptor Type 2–Dominated Cross-talk between Tumor Cells and Macrophages Drives Gastric Cancer Metastasis Zhijun Zhou, Guanggai Xia, Zhen Xiang et al. · Clinical Cancer Research Open access	22 Feb 2019	135
16	Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer Carryn M. Anderson et al. · Journal of Clinical Oncology Open access	16 Oct 2019	126
17	Current Approaches and Challenges in Monitoring Treatment Responses in Breast Cancer Lindsey J. Graham, Matthew P. Shupe, Erika J Schneble et al. · Journal of Cancer Open access	2014	123
18	Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes Matthew D. Galsky et al. · European Urology	13 Dec 2017	114
19	Timing of surgical antimicrobial prophylaxis: a phase 3 randomised controlled trial William P. Weber et al. · The Lancet Infectious Diseases Open access	3 Apr 2017	114
20	Translational advances regarding hereditary breast cancer syndromes Michele Maiko Gage, Daniel J Wattendorf, Leonard R. Henry · Journal of Surgical Oncology	22 Mar 2012	113
21	A positive crosstalk between CXCR4 and CXCR2 promotes gastric cancer metastasis Zhenxian Xiang, Z-J Zhou, G-K Xia et al. · Oncogene	8 May 2017	100
22	Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study Pierre Chabot, Te‐Chun Hsia, Jeong‐Seon Ryu et al. · Journal of Neuro-Oncology Open access	21 Sep 2016	95
23	Patients’ Perceptions of Nurses’ Skill Peggy Rupp Wysong, Evelyn Jane Driver · Critical Care Nurse	Aug 2009	89
24	Fractionated radioimmunotherapy with 90 Y‐clivatuzumab tetraxetan and low‐dose gemcitabine is active in advanced pancreatic cancer Allyson J. Ocean, Kenneth Lee Pennington, Michael J. Guarino et al. · Cancer Open access	8 May 2012	84
25	Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer Suresh S. Ramalingam, Normand Blais, Julien Mazières et al. · Clinical Cancer Research Open access	11 Oct 2016	82
26	Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology Shadia Ibrahim Jalal, Heather Riggs, A. Melnyk et al. · Annals of Oncology Open access	10 Dec 2011	79
27	Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study Brian G. Czito, Dustin A. Deming, Gayle Jameson et al. · The Lancet. Gastroenterology & hepatology	27 Mar 2017	77
28	Yttrium 90 Microsphere Selective Internal Radiation Treatment of Hepatic Colorectal Metastases Seza A. Güleç · Archives of Surgery	Jul 2007	77
29	The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy Seza A. Güleç, Rekha R. Suthar, Tushar C. Barot et al. · European Journal of Nuclear Medicine and Molecular Imaging	Apr 2011	77
30	Urgent surgery after emergency presentation for colorectal cancer has no impact on overall and disease-free survival: a propensity score analysis Benjamin Weixler, René Warschkow, Michaela Ramser et al. · BMC Cancer Open access	11 Mar 2016	72
31	Preoperative Y-90 microsphere selective internal radiation treatment for tumor downsizing and future liver remnant recruitment: a novel approach to improving the safety of major hepatic resections Seza Güleç, Kenneth Lee Pennington, Michael Hall et al. · World Journal of Surgical Oncology Open access	8 Jan 2009	72
32	A Phase I Dose-Escalation Trial of Single-Fraction Stereotactic Radiation Therapy for Liver Metastases Jeffrey John Meyer, Ryan D. Foster, Naama Lev‐Cohain et al. · Annals of Surgical Oncology Open access	11 May 2015	70
33	Profile of nintedanib in the treatment of solid tumors: the evidence to date Niranjan Awasthi, Roderich Egbert Schwarz · OncoTargets and Therapy Open access	Dec 2015	68
34	PET probe-guided surgery: applications and clinical protocol Seza A. Güleç, Erica Hoenie, Richard Hostetter et al. · World Journal of Surgical Oncology Open access	7 Jun 2007	65
35	Should COVID-19 Mother Breastfeed her Newborn Child? A Literature Review on the Safety of Breastfeeding for Pregnant Women with COVID-19 Harshil Bhatt · Current Nutrition Reports Open access	4 Jan 2021	64
36	Iatrogenic air embolism: pathoanatomy, thromboinflammation, endotheliopathy, and therapies Phillip L. Marsh et al. · Frontiers in Immunology Open access	19 Sep 2023	63
37	Current Approaches and Challenges in Early Detection of Breast Cancer Recurrence Erika J Schneble, Lindsey J. Graham, Matthew P. Shupe et al. · Journal of Cancer Open access	2014	63
38	PET-Probe: Evaluation of Technical Performance and Clinical Utility of a Handheld High-Energy Gamma Probe in Oncologic Surgery Seza A. Güleç, Farhad Daghighian, Richard Essner · Annals of Surgical Oncology	24 Jul 2006	60
39	Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia Alexey Valeryevich Danilov, Charles Herbaux, Harriet S. Walter et al. · Clinical Cancer Research Open access	10 Mar 2020	59
40	Utility of the Voice Handicap Index as an Indicator of Postthyroidectomy Voice Dysfunction Nancy Pearl Solomon, Leah Bernadette Helou, Leonard R. Henry et al. · Journal of Voice	5 Jan 2013	58
41	Posttherapy Radiation Safety Considerations in Radiomicrosphere Treatment with 90Y-Microspheres Seza A. Güleç, Julian Siegel · Journal of Nuclear Medicine Open access	16 Nov 2007	56
42	Voice Outcomes after Total Thyroidectomy, Partial Thyroidectomy, or Non-Neck Surgery Using a Prospective Multifactorial Assessment Diego A. Vicente, Nancy Pearl Solomon, Itzhak Avital et al. · Journal of the American College of Surgeons	21 Mar 2014	55
43	Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer Niranjan Awasthi, David Kronenberger, Alexis Stefaniak et al. · Cancer Letters	30 May 2019	53
44	OX40 expression enhances the prognostic significance of CD8 positive lymphocyte infiltration in colorectal cancer Benjamin Weixler, Eleonora Cremonesi, Roberto Pietro Sorge et al. · Oncotarget Open access	29 Sep 2015	52
45	A Comparison of Five Competing Lymph Node Staging Schemes in a Cohort of Resectable Gastric Cancer Patients David D. Smith, Rebecca A. Nelson, Roderich Egbert Schwarz · Annals of Surgical Oncology	17 Nov 2013	51
46	In vivo targeting of cell death using a synthetic fluorescent molecular probe B. Smith, Bryan A. Smith, Shuzhang Xiao et al. · APOPTOSIS Open access	16 Apr 2011	51
47	Phase II Study of Gemcitabine plus Docetaxel in Advanced Pancreatic Cancer: A Hoosier Oncology Group Study Bryan Paul Schneider, Kristen N. Ganjoo, David E. Seitz et al. · Oncology	2003	42
48	PET probe‐guided surgery Seza A. Güleç · Journal of Surgical Oncology	28 Aug 2007	41
49	A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma Sumanta Kumar Pal et al. · Clinical Cancer Research Open access	18 Mar 2015	40
50	Yttrium-90 Microsphere-selective Internal Radiation Therapy With Chemotherapy (Chemo-SIRT) for Colorectal Cancer Liver Metastases Seza Güleç, Kenneth Lee Pennington, J. Wheeler et al. · American Journal of Clinical Oncology	13 Dec 2012	39

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.